Remove Pages,Columns,Lines where

U.S. Patient and Trademask Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10538163	
INFORMATION DIGGS COURS	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Dr. M		Markus ANLIKER	
( Not for submission under 37 CFR 1.99)	Art Unit		1615	
(Not for Submission under or or it many	Examiner Name			
	Attorney Docket Number	er .	TMEY-00101-NUS	

U.S.PATENTS

Initial*	No.				int Passa s Appear	ges or R	elevant				
	1	2747574		1956-05	5-29	LORENZO					
	2	3667465		1972-06	5-06	VOSS					
	3	6375956	B1	2002-04	1-23	HERMELIN e	t al.				
If you wis	h to a	dd additional U.S. Pater	t citatio	n informa	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns, ant Passa; s Appear		
		Publication Number			tion			Releva	nt Passa		
Initial*	No 1	Publication Number	Code <sup>1</sup>	Date		of cited Docu	iment	Releva Figure	ant Passa s Appear		
Initial*	No 1		Code <sup>1</sup>	Date	citatio	of cited Docu	ument	Releva Figure	ant Passa s Appear		
Initial*	No 1		Code <sup>1</sup>	Date plication FOREIG	citatio	of cited Docu	ument	Relevs Figure	ant Passa s Appear	jumns,Li evant or Relev	nes

### 

2	0 185 968	EP	A2	1986-07-02	SCHWARZ GMBH	
3	1 405 623	EP	A1	2004-04-07	ANLIKER	
4	63-28717	JP	A	1988-11-24	SHIGESABURO	
5	62-192320	JP	A	1987-08-22	KAO CORP	
6	62-175420	JP	A	1987-08-01	KAO CORP	

If you wish to add additional Foreign Patent Document clation information please click the Add button | Add |
NON-PATENT LITERATURE DOCUMENTS | Remove|

Examiner | Cite | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item initialis\* No | (block magazine, purnal, serial symposium, catalog, etc), date, pages(s), volume-issue number(s), pages(s), volume-issue number(s), pages (s), volume-issue number(s), pages (s)

1

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

-----

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Nnt Cotes of USPTO Patent Documents at invent USPTO CODY or MPPS 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO) Standard ST3.) <sup>2</sup> The Japanese patent focument, the included on the year of the region of the Empirer or many precise the sent amountment of the patent document. <sup>4</sup> Nnt of Cocument by the appropriate symbols as andicated on the document under WIPO Standard ST1.6 if possible, <sup>2</sup> Applicant is to place a check mark here if Empirels inauguage translation is addated.

Examiner Signature

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10538163
Filing Date		
First Named Inventor	Dr. M	larkus ANLIKER
Art Unit		1615
Examiner Name		
Attorney Docket Numb	er	TMEY-00101-NUS

### CERTIFICATION STATEMENT

Please see 37	7 CFR 1.	97 and 1.	98 to make the	e appropriate	selection(s):
---------------	----------	-----------	----------------	---------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

## ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Matthias Scholl/	Date (YYYY-MM-DD)	2006-04-08
Name/Print	Dr. Matthias SCHOLL	Registration Number	54947

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.511.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.32.313-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the principal principal

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as and of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4U S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of the
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.